首页 > 最新文献

Journal of Endocrinological Investigation最新文献

英文 中文
Correction: Who and how to screen for endogenous hypercortisolism in adrenal and pituitary incidentaloma. 更正:肾上腺和垂体偶发瘤中内源性皮质醇增多症的筛查对象和筛查方法。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-11-09 DOI: 10.1007/s40618-024-02489-x
Kimberly Coscia, Martina Verrienti, Guido Di Dalmazi, Maria Chiara Zatelli
{"title":"Correction: Who and how to screen for endogenous hypercortisolism in adrenal and pituitary incidentaloma.","authors":"Kimberly Coscia, Martina Verrienti, Guido Di Dalmazi, Maria Chiara Zatelli","doi":"10.1007/s40618-024-02489-x","DOIUrl":"https://doi.org/10.1007/s40618-024-02489-x","url":null,"abstract":"","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesity. 更正:谁以及如何筛查 2 型糖尿病或肥胖症患者的内源性皮质醇增多症。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-11-09 DOI: 10.1007/s40618-024-02487-z
Valentina Guarnotta, Carla Giordano, Giuseppe Reimondo
{"title":"Correction: Who and how to screen for endogenous hypercortisolism in type 2 diabetes mellitus or obesity.","authors":"Valentina Guarnotta, Carla Giordano, Giuseppe Reimondo","doi":"10.1007/s40618-024-02487-z","DOIUrl":"https://doi.org/10.1007/s40618-024-02487-z","url":null,"abstract":"","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: Cushing syndrome in paediatric population: who and how to screen. 更正:儿科库欣综合征:筛查对象和筛查方法。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-11-09 DOI: 10.1007/s40618-024-02485-1
Laura Chioma, Giuseppa Patti, Marco Cappa, Mohamad Maghnie
{"title":"Correction: Cushing syndrome in paediatric population: who and how to screen.","authors":"Laura Chioma, Giuseppa Patti, Marco Cappa, Mohamad Maghnie","doi":"10.1007/s40618-024-02485-1","DOIUrl":"https://doi.org/10.1007/s40618-024-02485-1","url":null,"abstract":"","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142630477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anxiety, depression and acromegaly: a systematic review. 焦虑、抑郁与肢端肥大症:系统综述。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-11-07 DOI: 10.1007/s40618-024-02483-3
Orlando Silvestro, Trine Lund-Jacobsen, Francesco Ferraù, Elena Sofia Blanca, Antonino Catalano, Giorgio Sparacino, Peter Schwarz, Salvatore Cannavò, Gabriella Martino

Purpose: scientific literature highlights risk factors linked to the onset of psychopathology in different medical pathological contexts. Acromegaly is a rare condition, particularly noteworthy due to the associated clinical psychological features. This research aimed at understanding the main psychopathological outcomes related to acromegaly, with particular emphasis to anxiety and depression.

Methods: In January 2024, in line with PRISMA guidelines, a systematic search based on PubMed, Scopus, Web of Science and PsycInfo was conducted to detect studies considering anxiety, depression and alexithymia in patients suffering from acromegaly. The Keywords used for the search phase were "Acromegaly" AND "Depression" OR "Anxiety" OR "Alexithymia".

Results: Fifty-five studies were eligible. Anxiety and depression were significantly present in patients with acromegaly, with prevalence rates variable based on disease status and psycho-diagnostic instruments. None of the included studies reported alexithymia in patients with acromegaly. No significant difference was found regarding anxiety and depressive symptoms in patients with acromegaly in comparison with patients suffering from different pituitary diseases and chronic conditions. Anxiety and depression were associated with lower perceived HR-QoL, presence of comorbidity, joint issues, delayed diagnosis, disease duration and body image concerns.

Conclusions: Anxiety and depression may be encountered in patients with acromegaly, impacting HR-QoL and the course of the disease. This systematic review suggests that a deeper evaluation of clinical psychological features in patients suffering from acromegaly is needed. Particularly, the early detection of clinical psychological symptoms may lead to multi-integrate interventions promoting individuals' well-being and a better HR-QoL.

目的:科学文献强调了在不同的医学病理背景下与精神病理学发病有关的风险因素。肢端肥大症是一种罕见疾病,其相关的临床心理特征尤其值得注意。本研究旨在了解与肢端肥大症相关的主要心理病理结果,尤其侧重于焦虑和抑郁:2024 年 1 月,根据 PRISMA 指南,我们在 PubMed、Scopus、Web of Science 和 PsycInfo 上进行了系统检索,以发现有关肢端肥大症患者焦虑、抑郁和自闭症的研究。搜索阶段使用的关键词为 "肢端肥大症 "和 "抑郁 "或 "焦虑 "或 "亚历山大症":结果:55 项研究符合条件。焦虑和抑郁在肢端肥大症患者中明显存在,患病率因疾病状态和心理诊断工具而异。所纳入的研究均未报告肢端肥大症患者有自闭症。研究发现,肢端肥大症患者的焦虑和抑郁症状与患有不同垂体疾病和慢性病的患者相比没有明显差异。焦虑和抑郁与较低的心率质生活感知、合并症、关节问题、诊断延迟、病程和身体形象问题有关:结论:肢端肥大症患者可能会出现焦虑和抑郁,从而影响其心率-质量-生活水平和病程。本系统综述表明,需要对肢端肥大症患者的临床心理特征进行更深入的评估。特别是,及早发现临床心理症状,可以采取多种综合干预措施,促进患者的身心健康,提高其心率质生活水平。
{"title":"Anxiety, depression and acromegaly: a systematic review.","authors":"Orlando Silvestro, Trine Lund-Jacobsen, Francesco Ferraù, Elena Sofia Blanca, Antonino Catalano, Giorgio Sparacino, Peter Schwarz, Salvatore Cannavò, Gabriella Martino","doi":"10.1007/s40618-024-02483-3","DOIUrl":"https://doi.org/10.1007/s40618-024-02483-3","url":null,"abstract":"<p><strong>Purpose: </strong>scientific literature highlights risk factors linked to the onset of psychopathology in different medical pathological contexts. Acromegaly is a rare condition, particularly noteworthy due to the associated clinical psychological features. This research aimed at understanding the main psychopathological outcomes related to acromegaly, with particular emphasis to anxiety and depression.</p><p><strong>Methods: </strong>In January 2024, in line with PRISMA guidelines, a systematic search based on PubMed, Scopus, Web of Science and PsycInfo was conducted to detect studies considering anxiety, depression and alexithymia in patients suffering from acromegaly. The Keywords used for the search phase were \"Acromegaly\" AND \"Depression\" OR \"Anxiety\" OR \"Alexithymia\".</p><p><strong>Results: </strong>Fifty-five studies were eligible. Anxiety and depression were significantly present in patients with acromegaly, with prevalence rates variable based on disease status and psycho-diagnostic instruments. None of the included studies reported alexithymia in patients with acromegaly. No significant difference was found regarding anxiety and depressive symptoms in patients with acromegaly in comparison with patients suffering from different pituitary diseases and chronic conditions. Anxiety and depression were associated with lower perceived HR-QoL, presence of comorbidity, joint issues, delayed diagnosis, disease duration and body image concerns.</p><p><strong>Conclusions: </strong>Anxiety and depression may be encountered in patients with acromegaly, impacting HR-QoL and the course of the disease. This systematic review suggests that a deeper evaluation of clinical psychological features in patients suffering from acromegaly is needed. Particularly, the early detection of clinical psychological symptoms may lead to multi-integrate interventions promoting individuals' well-being and a better HR-QoL.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607106","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Increased risk of breast cancer among premenopausal women with pituitary gland disorders in Taiwan: a population-based matched-cohort study. 台湾患有垂体疾病的绝经前妇女罹患乳腺癌的风险增加:一项基于人群的匹配队列研究。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-11-07 DOI: 10.1007/s40618-024-02482-4
Ching-Chun Lin, Chun-Ji Lin, Yi-Chen Hsieh, Jiann-Her Lin, Huei-Yu Tsai, Chih-Yi Wu, Hung-Yi Chiou

Purpose: An association between pituitary gland disorders and breast cancer remains controversial. We examined the prevalence and risk of breast cancer over a 15-year follow-up period or until diagnosed as breast cancer among premenopausal women (12-49 years old) with pituitary gland disorders in Taiwan.

Methods: This retrospective matched-cohort study included 52,265 individuals each in the study group (women with pituitary gland disorders) and the matched control group from 2000 to 2004 identified using Taiwan's National Health Insurance Research Database. We compared sociodemographic characteristics and medical disorders between the two groups and examined the differences in clinicopathological characteristics of breast cancer. We also estimated the risk of breast cancer over 15 years of follow-up (median follow-up time = 11.2 years).

Results: Overall, 924 (1.8%) and 734 (1.4%) patients in the study and control groups, respectively, were diagnosed as having breast cancer (p < 0.001). Over the 15-year follow-up period, the study group had a 1.16-fold (95% confidence interval [CI] = 1.04-1.29, p < 0.05) increased risk of breast cancer compared with the control group. This risk was particularly pronounced in the 20-29 and 30-39 age groups (adjusted hazard ratio = 1.46 and 1.25, respectively; 95% CI = 1.15-1.86 and 1.07-1.44, p value < 0.01, respectively).

Conclusion: Our findings reveal a relationship between pituitary gland disorders and breast cancer among premenopausal women in an Asian country. Physicians should check for signs of breast cancer in premenopausal women with pituitary gland disorders for early detection and treatment. Future studies should confirm our findings and clarify the causal relationship.

目的:垂体疾病与乳腺癌之间的关系仍存在争议。我们研究了台湾患有垂体疾病的绝经前女性(12-49 岁)在 15 年随访期内或被诊断为乳腺癌之前的乳腺癌发病率和风险:这项回顾性配对队列研究纳入了研究组(患有垂体疾病的女性)和配对对照组各 52,265 人,研究时间为 2000 年至 2004 年。我们比较了两组人的社会人口学特征和疾病情况,并研究了乳腺癌临床病理特征的差异。我们还估算了 15 年随访期间(中位随访时间 = 11.2 年)患乳腺癌的风险:总体而言,研究组和对照组分别有 924 名(1.8%)和 734 名(1.4%)患者被确诊为乳腺癌(P 结论:我们的研究结果表明,垂体功能障碍与乳腺癌之间存在关联:我们的研究结果表明,在一个亚洲国家,绝经前妇女的垂体功能紊乱与乳腺癌之间存在一定关系。医生应检查患有垂体疾病的绝经前妇女是否有乳腺癌的迹象,以便及早发现和治疗。未来的研究应证实我们的发现,并阐明其中的因果关系。
{"title":"Increased risk of breast cancer among premenopausal women with pituitary gland disorders in Taiwan: a population-based matched-cohort study.","authors":"Ching-Chun Lin, Chun-Ji Lin, Yi-Chen Hsieh, Jiann-Her Lin, Huei-Yu Tsai, Chih-Yi Wu, Hung-Yi Chiou","doi":"10.1007/s40618-024-02482-4","DOIUrl":"https://doi.org/10.1007/s40618-024-02482-4","url":null,"abstract":"<p><strong>Purpose: </strong>An association between pituitary gland disorders and breast cancer remains controversial. We examined the prevalence and risk of breast cancer over a 15-year follow-up period or until diagnosed as breast cancer among premenopausal women (12-49 years old) with pituitary gland disorders in Taiwan.</p><p><strong>Methods: </strong>This retrospective matched-cohort study included 52,265 individuals each in the study group (women with pituitary gland disorders) and the matched control group from 2000 to 2004 identified using Taiwan's National Health Insurance Research Database. We compared sociodemographic characteristics and medical disorders between the two groups and examined the differences in clinicopathological characteristics of breast cancer. We also estimated the risk of breast cancer over 15 years of follow-up (median follow-up time = 11.2 years).</p><p><strong>Results: </strong>Overall, 924 (1.8%) and 734 (1.4%) patients in the study and control groups, respectively, were diagnosed as having breast cancer (p < 0.001). Over the 15-year follow-up period, the study group had a 1.16-fold (95% confidence interval [CI] = 1.04-1.29, p < 0.05) increased risk of breast cancer compared with the control group. This risk was particularly pronounced in the 20-29 and 30-39 age groups (adjusted hazard ratio = 1.46 and 1.25, respectively; 95% CI = 1.15-1.86 and 1.07-1.44, p value < 0.01, respectively).</p><p><strong>Conclusion: </strong>Our findings reveal a relationship between pituitary gland disorders and breast cancer among premenopausal women in an Asian country. Physicians should check for signs of breast cancer in premenopausal women with pituitary gland disorders for early detection and treatment. Future studies should confirm our findings and clarify the causal relationship.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving the radiological prediction of surgical resection of nonfunctioning pituitary adenomas. 改进对无功能垂体腺瘤手术切除的放射学预测。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-11-05 DOI: 10.1007/s40618-024-02479-z
Eduardo Giardini, Monique Alvares Barbosa, Nina Ventura, Paulo José da Mata Pereira, André Guasti, Paulo Niemeyer, Felipe Andreiuolo, Leila Chimelli, Leandro Kasuki, Mônica R Gadelha

Purpose: Nonfunctioning pituitary adenomas (NFPAs) are benign tumors growing in the sellar region. Total surgical excision of the lesion is recommended as the preferred treatment choice with preservation of adjacent structures. The objective is to establish a radiological score to predict the feasibility of NFPA total surgical excision.

Methods: Patients with treatment-naïve NFPA who underwent a transsphenoidal approach and sellar magnetic resonance imaging (MRI) in the preoperative period and 3 months after surgery were included. Data on age, sex, tumor diameter, extrasellar extension, postoperative cure rates, and hormone and transcription factor expression were collected. A combined score was proposed based on Knosp and SIPAP classifications. We proposed 3 classification groups depending on the tumoral extension to the suprasellar, infrasellar, anterior and posterior directions of the sellar region.

Results: A total of 164 patients were included in the study, and 85 (52%) were female. Total excision was obtained in 46% (n = 75) of the patients. The majority of tumors were of gonadotrophic lineage (59%), followed by corticotrophic (17%) and other less common types. Largest tumor diameter was 6.8 cm [mean 3.8 cm (± 1.1 cm)]. From the established groups, 10 patients were classified in Group I, of whom 8 (80%) patients underwent total excision, 115 patients were classified in Group II, of whom 58 (50%) underwent complete excision and 39 patients in Group III, of whom 9 (23%) underwent complete excision (p value < 0.001).

Conclusion: The newly proposed score helps to determine the feasibility of total NFPA excision, allowing for better surgical planning and predictions of postoperative outcomes.

目的:无功能垂体腺瘤(NFPA)是生长在蝶窦区域的良性肿瘤。在保留邻近结构的前提下,建议首选手术切除病灶。我们的目的是建立一个放射学评分来预测NFPA全切手术的可行性:方法:纳入经蝶窦入路、术前和术后 3 个月接受蝶窦磁共振成像(MRI)检查的未经治疗的 NFPA 患者。收集了有关年龄、性别、肿瘤直径、鞍外扩展、术后治愈率以及激素和转录因子表达的数据。根据 Knosp 和 SIPAP 的分类提出了一个综合评分。根据肿瘤向蝶鞍上、蝶鞍下、蝶鞍前和蝶鞍后方向的延伸,我们提出了 3 个分类组:共有 164 名患者参与研究,其中 85 名(52%)为女性。46%的患者(75人)接受了全切除术。大多数肿瘤属于性腺营养型(59%),其次是皮质营养型(17%)和其他较少见的类型。最大肿瘤直径为 6.8 厘米[平均 3.8 厘米(± 1.1 厘米)]。在已确定的组别中,10 名患者被归入 I 组,其中 8 名(80%)患者接受了全切术;115 名患者被归入 II 组,其中 58 名(50%)患者接受了全切术;39 名患者被归入 III 组,其中 9 名(23%)患者接受了全切术(P 值 结论:新提出的评分有助于确定肿瘤的类型:新提出的评分有助于确定全切 NFPA 的可行性,从而更好地制定手术计划和预测术后效果。
{"title":"Improving the radiological prediction of surgical resection of nonfunctioning pituitary adenomas.","authors":"Eduardo Giardini, Monique Alvares Barbosa, Nina Ventura, Paulo José da Mata Pereira, André Guasti, Paulo Niemeyer, Felipe Andreiuolo, Leila Chimelli, Leandro Kasuki, Mônica R Gadelha","doi":"10.1007/s40618-024-02479-z","DOIUrl":"https://doi.org/10.1007/s40618-024-02479-z","url":null,"abstract":"<p><strong>Purpose: </strong>Nonfunctioning pituitary adenomas (NFPAs) are benign tumors growing in the sellar region. Total surgical excision of the lesion is recommended as the preferred treatment choice with preservation of adjacent structures. The objective is to establish a radiological score to predict the feasibility of NFPA total surgical excision.</p><p><strong>Methods: </strong>Patients with treatment-naïve NFPA who underwent a transsphenoidal approach and sellar magnetic resonance imaging (MRI) in the preoperative period and 3 months after surgery were included. Data on age, sex, tumor diameter, extrasellar extension, postoperative cure rates, and hormone and transcription factor expression were collected. A combined score was proposed based on Knosp and SIPAP classifications. We proposed 3 classification groups depending on the tumoral extension to the suprasellar, infrasellar, anterior and posterior directions of the sellar region.</p><p><strong>Results: </strong>A total of 164 patients were included in the study, and 85 (52%) were female. Total excision was obtained in 46% (n = 75) of the patients. The majority of tumors were of gonadotrophic lineage (59%), followed by corticotrophic (17%) and other less common types. Largest tumor diameter was 6.8 cm [mean 3.8 cm (± 1.1 cm)]. From the established groups, 10 patients were classified in Group I, of whom 8 (80%) patients underwent total excision, 115 patients were classified in Group II, of whom 58 (50%) underwent complete excision and 39 patients in Group III, of whom 9 (23%) underwent complete excision (p value < 0.001).</p><p><strong>Conclusion: </strong>The newly proposed score helps to determine the feasibility of total NFPA excision, allowing for better surgical planning and predictions of postoperative outcomes.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Semaglutide cuts kidney risk in obesity. 塞马鲁肽降低肥胖症患者的肾脏风险
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-11-04 DOI: 10.1007/s40618-024-02494-0
Dario Giugliano, Luca De Nicola, Maria Ida Maiorino, Katherine Esposito
{"title":"Semaglutide cuts kidney risk in obesity.","authors":"Dario Giugliano, Luca De Nicola, Maria Ida Maiorino, Katherine Esposito","doi":"10.1007/s40618-024-02494-0","DOIUrl":"https://doi.org/10.1007/s40618-024-02494-0","url":null,"abstract":"","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The assessment of urinary sexual hormones within minipuberty and correlations with anthropometrics in a cohort of healthy term children. 在一组健康的足月儿童中评估青春期尿液中的性激素以及与人体测量学的相关性。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-11-04 DOI: 10.1007/s40618-024-02493-1
Viola Trevisani, Lucia Palandri, Beatrice Righi, Domenico Maione, Lisa De Pasquale, Enrico Tagliafico, Chiarina Grisolia, Mara Tagliazucchi, Barbara Predieri, Lorenzo Iughetti, Elena Righi, Laura Lucaccioni

Introduction: Minipuberty follows different trends in boys and girls. Aim of our study was to explore timing and dynamics of minipuberty in healthy infants, analyzing urinary levels of sexual hormones. Moreover, we analyzed the association among HPG axis activity and linear growth, ano-genital distances (AGDs) in both sexes, and penile length in males.

Methods: Longitudinal cohort study in healthy term infants from birth to 6 months of life. Clinical evaluation (anthropometrics and AGDs) and urine sampling were performed at 0 (T0), 3 (T3), and 6 (T6) months. Urine samples were analyzed for gonadotropins and sex hormones.

Results: 165 participants were involved. The growth trend of our population was regular, as were the AGDs. Urinary hormones were correlated each other's. Specifically, in boys, the correlation coefficient between urinary FSH (uFSH) and urinary LH (uLH) decreased from T0 to T6, while between urinary Testosterone (uT) and uFSH increased. In girls, correlations between uFSH and urinary Estradiol (uE) were observed at each time point. Notably, several correlations between hormones and anthropometrics and AGDs were found; the most interesting correlation was found in males within uLH and PL (at T0 ρ: 0.323, p < 0.05 and at T3 ρ: 0.371, p < 0.01), whereas in females uFSH at T0 showed negative correlations with both length and body weight percentile at T3 (ρ: -0.505, p < 0.01 and ρ: -0.478, p < 0.01, respectively).

Conclusion: Urinary matrix has proved to be a valuable, practical, non-invasive and cheaper method for sexual hormone assessment.

导言男孩和女孩的性早熟趋势不同。我们的研究旨在通过分析尿液中的性激素水平,探讨健康婴儿青春期发育的时间和动态。此外,我们还分析了HPG轴活动与线性生长、两性生殖器外侧距离(AGDs)和男性阴茎长度之间的关系:方法:对出生至 6 个月的健康足月儿进行纵向队列研究。分别在婴儿出生 0 个月(T0)、3 个月(T3)和 6 个月(T6)时进行临床评估(人体测量和 AGDs)和尿样采集。对尿液样本进行了促性腺激素和性激素分析:结果:共有 165 人参与。结果:165 名参与者的生长趋势和 AGD 都很正常。尿液中的激素彼此相关。具体而言,在男孩中,尿 FSH(uFSH)和尿 LH(uLH)之间的相关系数从 T0 到 T6 有所下降,而尿睾酮(uT)和尿 FSH 之间的相关系数则有所上升。在女孩中,uFSH 和尿雌二醇(uE)之间在每个时间点都存在相关性。值得注意的是,激素与人体测量学和 AGDs 之间存在一些相关性;最有趣的相关性出现在男性 uLH 和 PL 之间(T0 ρ:0.323, p 结论:尿基质已被证明是一种有价值的、实用的、非侵入性的、成本更低的性激素评估方法。
{"title":"The assessment of urinary sexual hormones within minipuberty and correlations with anthropometrics in a cohort of healthy term children.","authors":"Viola Trevisani, Lucia Palandri, Beatrice Righi, Domenico Maione, Lisa De Pasquale, Enrico Tagliafico, Chiarina Grisolia, Mara Tagliazucchi, Barbara Predieri, Lorenzo Iughetti, Elena Righi, Laura Lucaccioni","doi":"10.1007/s40618-024-02493-1","DOIUrl":"https://doi.org/10.1007/s40618-024-02493-1","url":null,"abstract":"<p><strong>Introduction: </strong>Minipuberty follows different trends in boys and girls. Aim of our study was to explore timing and dynamics of minipuberty in healthy infants, analyzing urinary levels of sexual hormones. Moreover, we analyzed the association among HPG axis activity and linear growth, ano-genital distances (AGDs) in both sexes, and penile length in males.</p><p><strong>Methods: </strong>Longitudinal cohort study in healthy term infants from birth to 6 months of life. Clinical evaluation (anthropometrics and AGDs) and urine sampling were performed at 0 (T0), 3 (T3), and 6 (T6) months. Urine samples were analyzed for gonadotropins and sex hormones.</p><p><strong>Results: </strong>165 participants were involved. The growth trend of our population was regular, as were the AGDs. Urinary hormones were correlated each other's. Specifically, in boys, the correlation coefficient between urinary FSH (uFSH) and urinary LH (uLH) decreased from T0 to T6, while between urinary Testosterone (uT) and uFSH increased. In girls, correlations between uFSH and urinary Estradiol (uE) were observed at each time point. Notably, several correlations between hormones and anthropometrics and AGDs were found; the most interesting correlation was found in males within uLH and PL (at T0 ρ: 0.323, p < 0.05 and at T3 ρ: 0.371, p < 0.01), whereas in females uFSH at T0 showed negative correlations with both length and body weight percentile at T3 (ρ: -0.505, p < 0.01 and ρ: -0.478, p < 0.01, respectively).</p><p><strong>Conclusion: </strong>Urinary matrix has proved to be a valuable, practical, non-invasive and cheaper method for sexual hormone assessment.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142569558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Xenotropic and polytropic retrovirus receptor 1 (XPR1) promotes progression of papillary thyroid carcinoma via the BRAF-ERK1/2-P53 signaling pathway. 各向异性和多向性逆转录病毒受体1(XPR1)通过BRAF-ERK1/2-P53信号通路促进甲状腺乳头状癌的进展。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-11-02 DOI: 10.1007/s40618-024-02481-5
Yuanhao Su, Lin Mei, Yongke Wu, Cheng Li, Tiantian Jiang, Yiyuan Zhao, Xin Feng, Tingkai Sun, Yunhao Li, Zhidong Wang, Yuanyuan Ji

Background: Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Xenotropic and polytropic retrovirus receptor 1 (XPR1), identified as a cellular receptor, plays roles in many pathophysiological processes. However, the underlying function and molecular mechanisms of XPR1 in PTC remain unclear. Therefore, this study aimed to elucidate the role of XPR1 in the process of PTC and the potential mechanisms.

Methods: RNA-sequencing was performed for gene differential expression analysis in PTC patients' tissues. Immunohistochemical assay, real-time PCR, and western blotting assay were used to determine the expression of XPR1, BRAF, and P53 in PTC tissues. The function of XPR1 on the progression of PTC was explored using in vitro and in vivo experiments. The molecular mechanism of XPR1 was investigated using gene silencing, ELISA, immunofluorescence, western blotting, and real-time PCR assays.

Results: We found that XPR1 was markedly upregulated in PTC tissues compared to adjacent noncancerous tissues, suggesting that high expression of XPR1 could be correlated with poor patient disease-free survival in PTC. In addition, the expression of BRAF and P53 in PTC tissues was substantially higher than in adjacent noncancerous tissues. Silencing of XPR1 reduced the proliferation, migration, and invasion capacities of TPC-1 cells in vitro and effectively inhibited the tumorigenecity of PTC in vivo. More importantly, silencing of XPR1 in TPC-1 cells significantly decreased the expression of XPR1, BRAF, and P53 both in vitro and in vivo. Interestingly, we demonstrated that XPR1 may positively activate the BRAF-ERK-P53 signaling pathway, further promoting PTC progression.

Conclusion: The findings reveal a crucial role of XPR1 in PTC progression and prognosis via the BRAF-ERK1/2-P53 signaling pathway, providing potential therapeutic targets for treating PTC.

背景:甲状腺乳头状癌(PTC甲状腺乳头状癌(PTC)是最常见的甲状腺癌类型。异向性和多向性逆转录病毒受体 1(XPR1)被认为是一种细胞受体,在许多病理生理过程中发挥作用。然而,XPR1 在 PTC 中的潜在功能和分子机制仍不清楚。因此,本研究旨在阐明 XPR1 在 PTC 过程中的作用及其潜在机制:方法:对 PTC 患者组织进行 RNA 序列分析,以了解基因差异表达情况。方法:对 PTC 患者组织中的基因差异表达进行 RNA 序列分析,并通过免疫组化、实时 PCR 和 Western 印迹分析确定 XPR1、BRAF 和 P53 在 PTC 组织中的表达。通过体外和体内实验探讨了 XPR1 对 PTC 进展的作用。利用基因沉默、ELISA、免疫荧光、Western 印迹和实时 PCR 检测等方法研究了 XPR1 的分子机制:结果:我们发现,与邻近的非癌组织相比,XPR1在PTC组织中明显上调,这表明XPR1的高表达与PTC患者的无病生存率相关。此外,PTC 组织中 BRAF 和 P53 的表达也大大高于邻近的非癌组织。沉默 XPR1 降低了 TPC-1 细胞在体外的增殖、迁移和侵袭能力,并有效抑制了 PTC 在体内的致瘤性。更重要的是,在 TPC-1 细胞中沉默 XPR1 能显著降低 XPR1、BRAF 和 P53 在体外和体内的表达。有趣的是,我们证实 XPR1 可积极激活 BRAF-ERK-P53 信号通路,进一步促进 PTC 的进展:研究结果揭示了 XPR1 通过 BRAF-ERK1/2-P53 信号通路在 PTC 进展和预后中的关键作用,为治疗 PTC 提供了潜在的治疗靶点。
{"title":"Xenotropic and polytropic retrovirus receptor 1 (XPR1) promotes progression of papillary thyroid carcinoma via the BRAF-ERK1/2-P53 signaling pathway.","authors":"Yuanhao Su, Lin Mei, Yongke Wu, Cheng Li, Tiantian Jiang, Yiyuan Zhao, Xin Feng, Tingkai Sun, Yunhao Li, Zhidong Wang, Yuanyuan Ji","doi":"10.1007/s40618-024-02481-5","DOIUrl":"https://doi.org/10.1007/s40618-024-02481-5","url":null,"abstract":"<p><strong>Background: </strong>Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Xenotropic and polytropic retrovirus receptor 1 (XPR1), identified as a cellular receptor, plays roles in many pathophysiological processes. However, the underlying function and molecular mechanisms of XPR1 in PTC remain unclear. Therefore, this study aimed to elucidate the role of XPR1 in the process of PTC and the potential mechanisms.</p><p><strong>Methods: </strong>RNA-sequencing was performed for gene differential expression analysis in PTC patients' tissues. Immunohistochemical assay, real-time PCR, and western blotting assay were used to determine the expression of XPR1, BRAF, and P53 in PTC tissues. The function of XPR1 on the progression of PTC was explored using in vitro and in vivo experiments. The molecular mechanism of XPR1 was investigated using gene silencing, ELISA, immunofluorescence, western blotting, and real-time PCR assays.</p><p><strong>Results: </strong>We found that XPR1 was markedly upregulated in PTC tissues compared to adjacent noncancerous tissues, suggesting that high expression of XPR1 could be correlated with poor patient disease-free survival in PTC. In addition, the expression of BRAF and P53 in PTC tissues was substantially higher than in adjacent noncancerous tissues. Silencing of XPR1 reduced the proliferation, migration, and invasion capacities of TPC-1 cells in vitro and effectively inhibited the tumorigenecity of PTC in vivo. More importantly, silencing of XPR1 in TPC-1 cells significantly decreased the expression of XPR1, BRAF, and P53 both in vitro and in vivo. Interestingly, we demonstrated that XPR1 may positively activate the BRAF-ERK-P53 signaling pathway, further promoting PTC progression.</p><p><strong>Conclusion: </strong>The findings reveal a crucial role of XPR1 in PTC progression and prognosis via the BRAF-ERK1/2-P53 signaling pathway, providing potential therapeutic targets for treating PTC.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Romosozumab for the treatment of osteoporosis - a systematic review. 治疗骨质疏松症的 Romosozumab - 系统综述。
IF 5.4 2区 医学 Q1 Medicine Pub Date : 2024-11-02 DOI: 10.1007/s40618-024-02469-1
V-N Mäkinen, A S Sølling, M McClung, B L Langdahl

Introduction: Romosozumab, a new treatment of osteoporosis, is a monoclonal antibody that targets sclerostin and thereby exhibits a dual mechanism of action by stimulating bone formation and inhibiting bone resorption. This systematic review aims to assess the clinical efficacy and safety of romosozumab for treatment of primary and secondary osteoporosis.

Methods: A comprehensive literature search was conducted in October 2023 across multiple databases including Embase, PubMed and Cochrane Library. Randomized controlled trials (RCTs) and observational studies evaluating the impact of romosozumab on BMD, bone turnover markers (BTM), fracture outcomes, and its safety profile were included. Data extraction and quality assessment were performed independently by two reviewers in accordance with PRISMA guidelines.

Results: A total of 36 articles met the inclusion criteria. Romosozumab significantly increased BMD at the lumbar spine, total hip, and femoral neck compared to placebo and active comparators in patients with primary osteoporosis. Sequential therapy with romosozumab followed by antiresorptives maintained or further increased BMD and reduced fracture risk. Romosozumab was generally well tolerated, however, an imbalance in cardiovascular adverse event was observed in one large clinical trial. Observational studies supported these findings. Specific subgroups of patients with secondary osteoporosis were assessed, demonstrating overall positive outcomes with romosozumab treatment.

Conclusion: Romosozumab effectively increases BMD and reduces fracture risk, particularly when used as initial therapy in high fracture-risk patients. Sequential therapy with subsequent antiresorptive treatment optimizes long-term benefits. While generally well-tolerated, its cardiovascular safety profile requires further long-term studies to ensure its safety in clinical practice. Additional studies are needed to confirm efficacy and safety in patients with secondary osteoporosis.

简介罗莫司单抗是一种治疗骨质疏松症的新药,它是一种针对硬骨素的单克隆抗体,因此具有刺激骨形成和抑制骨吸收的双重作用机制。本系统综述旨在评估罗莫单抗治疗原发性和继发性骨质疏松症的临床疗效和安全性:方法:2023 年 10 月,我们在多个数据库(包括 Embase、PubMed 和 Cochrane Library)中进行了全面的文献检索。纳入了评估罗莫单抗对 BMD、骨转换标志物 (BTM)、骨折结果及其安全性影响的随机对照试验 (RCT) 和观察性研究。数据提取和质量评估由两名审稿人根据PRISMA指南独立完成:共有 36 篇文章符合纳入标准。在原发性骨质疏松症患者中,与安慰剂和活性比较药相比,Romosozumab能明显增加腰椎、全髋和股骨颈的BMD。使用 Romosozumab 后再使用抗骨质疏松药的序贯疗法可维持或进一步增加 BMD,并降低骨折风险。罗姆索单抗的耐受性普遍良好,但在一项大型临床试验中观察到心血管不良事件的不平衡。观察性研究也支持这些发现。对继发性骨质疏松症患者的特定亚组进行了评估,结果显示罗莫索珠单抗治疗的总体疗效良好:结论:罗莫索单抗能有效增加骨密度并降低骨折风险,尤其是在高骨折风险患者的初始治疗中。罗莫单抗与后续抗骨吸收治疗的序贯治疗可优化长期疗效。虽然总体上耐受性良好,但其心血管安全性还需要进一步的长期研究,以确保其在临床实践中的安全性。还需要更多的研究来确认其对继发性骨质疏松症患者的疗效和安全性。
{"title":"Romosozumab for the treatment of osteoporosis - a systematic review.","authors":"V-N Mäkinen, A S Sølling, M McClung, B L Langdahl","doi":"10.1007/s40618-024-02469-1","DOIUrl":"https://doi.org/10.1007/s40618-024-02469-1","url":null,"abstract":"<p><strong>Introduction: </strong>Romosozumab, a new treatment of osteoporosis, is a monoclonal antibody that targets sclerostin and thereby exhibits a dual mechanism of action by stimulating bone formation and inhibiting bone resorption. This systematic review aims to assess the clinical efficacy and safety of romosozumab for treatment of primary and secondary osteoporosis.</p><p><strong>Methods: </strong>A comprehensive literature search was conducted in October 2023 across multiple databases including Embase, PubMed and Cochrane Library. Randomized controlled trials (RCTs) and observational studies evaluating the impact of romosozumab on BMD, bone turnover markers (BTM), fracture outcomes, and its safety profile were included. Data extraction and quality assessment were performed independently by two reviewers in accordance with PRISMA guidelines.</p><p><strong>Results: </strong>A total of 36 articles met the inclusion criteria. Romosozumab significantly increased BMD at the lumbar spine, total hip, and femoral neck compared to placebo and active comparators in patients with primary osteoporosis. Sequential therapy with romosozumab followed by antiresorptives maintained or further increased BMD and reduced fracture risk. Romosozumab was generally well tolerated, however, an imbalance in cardiovascular adverse event was observed in one large clinical trial. Observational studies supported these findings. Specific subgroups of patients with secondary osteoporosis were assessed, demonstrating overall positive outcomes with romosozumab treatment.</p><p><strong>Conclusion: </strong>Romosozumab effectively increases BMD and reduces fracture risk, particularly when used as initial therapy in high fracture-risk patients. Sequential therapy with subsequent antiresorptive treatment optimizes long-term benefits. While generally well-tolerated, its cardiovascular safety profile requires further long-term studies to ensure its safety in clinical practice. Additional studies are needed to confirm efficacy and safety in patients with secondary osteoporosis.</p>","PeriodicalId":48802,"journal":{"name":"Journal of Endocrinological Investigation","volume":" ","pages":""},"PeriodicalIF":5.4,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Endocrinological Investigation
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1